Protagonist Therapeutics Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $178.57. The average 1-year stock price forecast is 23.28% higher than the current stock price, while the lowest is $149 (+2.87%) and the highest is $225 (+55.33%).

Price Target: $178.57 (+23.28%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$149	$178.57	$176.5	$225
Change	+2.87%	+23.28%	+21.85%	+55.33%

Analyst Ratings

The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	9	9	9	10	10	11
Buy	3	3	3	3	3	3
Hold	1	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	13	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tara Bancroft TD Cowen	TD Cowen	Buy Reiterates $155 → $160	Buy	Reiterates	$155 → $160	+10.46%	Oct 21, 2026
Geoff Meacham Citi	Citi	Buy Maintains $182	Buy	Maintains	$182	+25.65%	Oct 15, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $180	Buy	Maintains	$180	+24.27%	Oct 13, 2026
Will Soghikian Leerink Partners	Leerink Partners	Buy Initiates $150 → $190	Buy	Initiates	$150 → $190	+31.17%	Oct 12, 2026
Alice Nettleton UBS	UBS	Buy Initiates $184	Buy	Initiates	$184	+27.03%	Oct 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

549.03M

from 46.02M

1,093.12%

from 46.02M

Revenue Next Year

215.49M

from 549.03M

-60.75%

from 549.03M

EPS This Year

4.77

from -2.05

EPS Next Year

-0.10

from 4.77

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	27.36M	26.58M	60.00M	434.43M	46.02M	549.03M
Revenue Growth	-4.44%	-2.84%	125.73%	624.06%	-89.41%	1,093.12%
Gross Profit	27.36M	26.58M	60.00M	434.43M	46.02M	510.59M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	93.00%
Operating Income	-125.85M	-131.37M	-93.65M	252.84M	-158.13M	311.12M
Net Income	-125.55M	-127.39M	-78.96M	275.19M	-130.15M	326.20M
EPS	-	-	-	-	-2.05	4.77
Forward PE	-	-	-	36.33	59.76	30.39
Free Cash Flow	-	-	-	-	56.08M	322.33M
No. Analysts	-	-	-	-	-	13

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	586.5M
Avg	549.0M
Low	445.2M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	1,174.6%
Avg	1,093.1%
Low	867.5%

EPS Forecast

Chart

EPS	2026	2027	2028
High	5.74
Avg	4.77
Low	3.52

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-